Literature DB >> 19667270

Targeting signal transducer and activator of transcription signaling pathway in leukemias.

Mustafa Benekli1, Heinz Baumann, Meir Wetzler.   

Abstract

Signal transducer and activator of transcription (STAT) proteins comprise a seven-member family of latent cytoplasmic transcription factors that are activated through tyrosine phosphorylation by a variety of cytokines and growth factors. Aberrant activation of STATs accompanies malignant cellular transformation with resultant leukemogenesis. Constitutive activation of STATs has been demonstrated in various leukemias. A better understanding of the mechanisms of dysregulation of the STAT pathway and understanding of the cause and effect relationship in leukemogenesis may serve as a basis for designing novel therapeutic strategies directed against STATs. Mechanisms of STAT activation, the potential role of STAT signaling in leukemogenesis, and recent advances in drug discovery targeting the STAT pathway are the focus of this review.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19667270      PMCID: PMC2744278          DOI: 10.1200/JCO.2008.21.3264

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  115 in total

Review 1.  Transcription factor activity of STAT proteins: structural requirements and regulation by phosphorylation and interacting proteins.

Authors:  T Decker; P Kovarik
Journal:  Cell Mol Life Sci       Date:  1999-09       Impact factor: 9.261

2.  Stat3 as an oncogene.

Authors:  J F Bromberg; M H Wrzeszczynska; G Devgan; Y Zhao; R G Pestell; C Albanese; J E Darnell
Journal:  Cell       Date:  1999-08-06       Impact factor: 41.582

Review 3.  Retinoic acid and interferon signaling cross talk in normal and RA-resistant APL cells.

Authors:  M K Chelbi-Alix; L Pelicano
Journal:  Leukemia       Date:  1999-08       Impact factor: 11.528

4.  The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia.

Authors:  C Arnould; C Philippe; V Bourdon; M J Gr goire; R Berger; P Jonveaux
Journal:  Hum Mol Genet       Date:  1999-09       Impact factor: 6.150

5.  Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia.

Authors:  M F Johan; D T Bowen; M E Frew; A C Goodeve; J T Reilly
Journal:  Br J Haematol       Date:  2005-04       Impact factor: 6.998

6.  Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia.

Authors:  S Biethahn; F Alves; S Wilde; W Hiddemann; K Spiekermann
Journal:  Exp Hematol       Date:  1999-05       Impact factor: 3.084

7.  p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons.

Authors:  K C Goh; S J Haque; B R Williams
Journal:  EMBO J       Date:  1999-10-15       Impact factor: 11.598

8.  Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity.

Authors:  James Turkson; Shumin Zhang; Jay Palmer; Heidi Kay; Joseph Stanko; Linda B Mora; Said Sebti; Hua Yu; Richard Jove
Journal:  Mol Cancer Ther       Date:  2004-12       Impact factor: 6.261

9.  Inhibition of protein phosphatase 2A induces serine/threonine phosphorylation, subcellular redistribution, and functional inhibition of STAT3.

Authors:  A Woetmann; M Nielsen; S T Christensen; J Brockdorff; K Kaltoft; A M Engel; S Skov; C Brender; C Geisler; A Svejgaard; J Rygaard; V Leick; N Odum
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

10.  Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

Authors:  Richard M Stone; Daniel J DeAngelo; Virginia Klimek; Ilene Galinsky; Eli Estey; Stephen D Nimer; Wilson Grandin; David Lebwohl; Yanfeng Wang; Pamela Cohen; Edward A Fox; Donna Neuberg; Jennifer Clark; D Gary Gilliland; James D Griffin
Journal:  Blood       Date:  2004-09-02       Impact factor: 22.113

View more
  60 in total

1.  Novel mechanism for Fc{epsilon}RI-mediated signal transducer and activator of transcription 5 (STAT5) tyrosine phosphorylation and the selective influence of STAT5B over mast cell cytokine production.

Authors:  Nicholas A Pullen; Brian O Barnstein; Yves T Falanga; Zhengqi Wang; Ryo Suzuki; Tenchee D Lama Tamang; Michele C Khurana; Emily A Harry; Petr Draber; Kevin D Bunting; Kazuya Mizuno; Bridget S Wilson; John J Ryan
Journal:  J Biol Chem       Date:  2011-11-30       Impact factor: 5.157

2.  Dietary compounds as potent inhibitors of the signal transducers and activators of transcription (STAT) 3 regulatory network.

Authors:  Anne Trécul; Franck Morceau; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2012-01-25       Impact factor: 5.523

Review 3.  Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.

Authors:  Syed J Noor; Wei Tan; Gregory E Wilding; Laurie A Ford; Maurice Barcos; Sheila N J Sait; Annemarie W Block; James E Thompson; Eunice S Wang; Meir Wetzler
Journal:  Leuk Res       Date:  2010-08-19       Impact factor: 3.156

4.  Blockade of glioma proliferation through allosteric inhibition of JAK2.

Authors:  Kunyan He; Qi Qi; Chi-Bun Chan; Ge Xiao; Xia Liu; Carol Tucker-Burden; Liya Wang; Hui Mao; Xiang Lu; Frank E McDonald; Hongbo Luo; Qi-Wen Fan; William A Weiss; Shi-Yong Sun; Daniel J Brat; Keqiang Ye
Journal:  Sci Signal       Date:  2013-07-09       Impact factor: 8.192

Review 5.  Therapeutic modulators of STAT signalling for human diseases.

Authors:  Gabriella Miklossy; Tyvette S Hilliard; James Turkson
Journal:  Nat Rev Drug Discov       Date:  2013-08       Impact factor: 84.694

Review 6.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

7.  Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia.

Authors:  Dwella M Nelson; Biju Joseph; Joelle Hillion; Jodi Segal; Judith E Karp; Linda M S Resar
Journal:  Leuk Lymphoma       Date:  2011-07-05

8.  Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.

Authors:  Suhu Liu; Sarah R Walker; Erik A Nelson; Robert Cerulli; Michael Xiang; Patricia A Toniolo; Jun Qi; Richard M Stone; Martha Wadleigh; James E Bradner; David A Frank
Journal:  Mol Cancer Ther       Date:  2014-01-16       Impact factor: 6.261

9.  Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells.

Authors:  Daniel R Premkumar; Esther P Jane; Ian F Pollack
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

10.  STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6.

Authors:  Sarah R Walker; Erik A Nelson; Jennifer E Yeh; Luca Pinello; Guo-Cheng Yuan; David A Frank
Journal:  Mol Cell Biol       Date:  2013-05-28       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.